Trial · NCT07909889
Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer
NCT07909889, Phase 2, Not yet recruiting, Aarhus University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer. Trials, record NCT07909889. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909889
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer
- NCT number
- NCT07909889
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 32 participants, estimated
- Lead sponsor
- Aarhus University Hospital
- Conditions
- Breast Cancer (Early Breast Cancer), Obesity
- Interventions
- Semaglutide (Wegovy®)
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes79
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Completion of the 26-week semaglutide treatment phase meeting all composite feasibility criteria | At completion of 26 weeks of semaglutide treatment: trial week 26 in Arm A and trial week 52 in Arm B. | Percentage of participants who complete the assigned 26-week treatment phase while meeting all three criteria: no permanent discontinuation of prescribed adjuvant endocrine therapy; no permanent discontinuation of semaglutide; and administration of at least 21 of 26 planned weekly semaglutide injections. Endocrine therapy continuation is assessed from prescription records and self-reported intake; semaglutide adherence is assessed from electronic dosing diaries with pen reconciliation. The proportion will be reported with a 95% confidence interval. |
| Secondary | Adverse events during semaglutide treatment and post-treatment follow-up | From the first semaglutide dose to end of follow-up: trial weeks 0-52 in Arm A and 26-78 in Arm B. | Number and percentage of participants with adverse events and total number of events, characterized by event type, maximum severity according to CTCAE version 6.0, relationship to semaglutide and event outcome. |
| Secondary | Serious adverse events | From randomization to end of follow-up: up to 52 weeks in Arm A and 78 weeks in Arm B. | Number and percentage of participants with at least one serious adverse event and total number of serious adverse events during trial participation. |
| Secondary | Suspected unexpected serious adverse reactions | From randomization to end of follow-up: up to 52 weeks in Arm A and 78 weeks in Arm B. | Number and percentage of participants with at least one suspected unexpected serious adverse reaction and total number of such reactions during trial participation. |
| Secondary | Adverse events of special interest | From randomization to end of follow-up: up to 52 weeks in Arm A and 78 weeks in Arm B. | Number and percentage of participants with protocol-defined adverse events of special interest and number of events, reported separately by event category. |
| Secondary | Patient-reported symptomatic adverse events | At protocol-specified assessments from treatment start to end of follow-up: trial weeks 0-52 in Arm A and 26-78 in Arm B. | Patient-reported symptomatic adverse events assessed using selected PRO-CTCAE items, with frequency, severity, interference or presence reported separately as applicable. Item scores range from 0 to 4, or 0 to 1 for presence/absence, with higher values indicating greater symptom burden. |
| Secondary | Semaglutide dose interruptions | During the 26-week semaglutide treatment phase: trial weeks 0-26 in Arm A and 26-52 in Arm B. | Number and percentage of participants with a temporary interruption of semaglutide, number of interruptions and recorded reasons. |
| Secondary | Semaglutide dose reductions | During the 26-week semaglutide treatment phase: trial weeks 0-26 in Arm A and 26-52 in Arm B. | Number and percentage of participants with a reduction in semaglutide dose, number of dose reductions and recorded reasons. |
| Secondary | Permanent discontinuation of semaglutide | During the 26-week semaglutide treatment phase: trial weeks 0-26 in Arm A and 26-52 in Arm B. | Number and percentage of participants who permanently discontinue semaglutide, with reasons for discontinuation. |
| Secondary | Time to permanent discontinuation of semaglutide | During the 26-week semaglutide treatment phase: trial weeks 0-26 in Arm A and 26-52 in Arm B. | Time in days from the first semaglutide dose to permanent discontinuation during the assigned treatment phase. |
1 to 10 of 79Source ClinicalTrials.gov
See all 79 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909889
GET https://conductscience.org/api/trials/v1/NCT07909889/registered?page=2